Sangamo rises on bleeding disorder gene therapy trial data

Sangamo Therapeutics

24/07/2024 13:59

** Shares of gene therapy developer Sangamo Therapeutics
 SGMO.O  rise ~73.6% to 67 cents premarket
    ** SGMO says co and partner Pfizer's  PFE.N  gene therapy
for hemophilia A significantly cut the number of annual bleeding
episodes in patients with the rare disorder in a late-stage
study
    ** Says the therapy performed better than the current
standard treatment
    ** People with hemophilia have a fault in a gene that
regulates production of proteins called clotting factors,
leading to spontaneous as well as severe bleeding following
injuries or surgery
    ** Up to last close, stock was down 26.1% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))